Netupitant Antiemetic Coverage for Long-Delayed ADC Nausea
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiemetic regimens are ineffective in preventing nausea and vomiting beyond 120 hours following antibody-drug conjugate (ADC) and other long-acting emetogenic therapies, leading to detrimental effects on quality of life and treatment adherence, with emerging data indicating prolonged toxicity profiles.
Innovation Solution
Administering netupitant or its pharmaceutically acceptable salts, or a combination with palonosetron, to provide effective antiemetic coverage up to 480 hours, significantly surpassing the efficacy of aprepitant and fosaprepitant regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If standard antiemetic regimens (aprepitant, fosaprepitant) are used, then nausea and vomiting are prevented during the acute and delayed phases (0-120 hours), but they are ineffective in preventing nausea and vomiting beyond 120 hours
Solution Approach 1:
The patent applies parameter changes by switching from aprepitant/fosaprepitant (with shorter duration of action) to netupitant (with extended duration of action). Netupitant maintains NK1 receptor occupancy above 90% for up to 480 hours, whereas aprepitant and fosaprepitant fall below effective thresholds after 120 hours. This parameter change in drug selection directly resolves the contradiction by extending the duration of antiemetic effect while maintaining reliability in the long-delayed phase.
2Duration of action of moving object
If antiemetic treatment is extended beyond 120 hours, then coverage of long-delayed phase is improved, but no optimal dosing regimen has been established
Solution Approach 1:
The patent implements continuity of useful action through a simplified dosing regimen: a single 300 mg oral dose of netupitant provides continuous effective NK1 receptor occupancy (above 90%) for up to 480 hours. This single-dose approach ensures continuous antiemetic coverage throughout the entire long-delayed phase without requiring multiple administrations or complex scheduling, thereby extending duration while reducing dosing regimen complexity.
3Reliability
If netupitant is administered at 300 mg, then NK1 receptor occupancy exceeds 90% for up to 480 hours, but this dosage has not been previously evaluated for ADC therapies
Solution Approach 1:
The patent applies preliminary action by conducting comprehensive clinical evaluation of the 300 mg netupitant dose specifically for ADC therapies before this dosage was previously tested in this context. The study pre-establishes the effectiveness of this dosage regimen for the long-delayed phase (up to 480 hours) in ADC patients, thereby eliminating the need for future clinicians to wait for additional evaluation time. This preliminary characterization directly resolves the contradiction by establishing reliable dosing guidance in advance.
Data Source
AI summary
Methods of preventing the side effects of antibody drug conjugate therapies and other long acting emetogenic therapies such as nausea and vomiting, particularly in the long-delayed phase (i.e. >120 hours).